Implementation of DOT statutes 49 U.S.C.  41310(A), 49 U.S.C.  44902(B), 49 U.S.C.  41501, and 49 U.S.C.  41704, regarding cargo transport. Healthcare issues related to clinical laboratories; 

FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; 

H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act, H.R. 3235, the Access to Genetic Counselor Services Act, and S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare, Medicaid and TRICARE coverage and reimbursement for laboratory services and reforms to the Clinical Laboratory Fee Schedule;

Federal policy relating to drug development; 

Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); 

Federal policy relating to subject matter eligibility for patents of laboratory tests; and

H.R. 3630, the No Surprises Act, H.R. 2328, the Reauthorizing and Extending Americas Community Health (REACH) Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
TRA - Transportation HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 South Spring Street, Burlington, NC, 27215, US
DONALD HORTON KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL